Log in

Relevant bibliographies by topics / Myeloma patients / Journal articles

To see the other types of publications on this topic, follow the link: Myeloma patients.

Journal articles on the topic 'Myeloma patients'

Author: Grafiati

Published: 4 June 2021

Last updated: 20 February 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Myeloma patients.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Do, T. H., H. E. Johnsen, E. Kjærsgaard, E. Taaning, and I. M. Svane. "Impaired circulating myeloid DCs from myeloma patients." Cytotherapy 6, no. 3 (June 2004): 196–203. http://dx.doi.org/10.1080/14653240410006004.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Vlossak, Donnaleen, and Margaret I. Fitch. "Le myélome multiple : la perspective des patients." Canadian Oncology Nursing Journal 18, no. 3 (2008): 146–51. http://dx.doi.org/10.5737/1181912x183146151.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Demircioğlu, Sinan, Gülçin Miyase Sönmez, Ali Doğan, Ömer Ekinci, and Cengiz Demir. "Incidence of Extramedullary Myeloma in Multiple Myeloma Patients." Van Medical Journal 26, no. 3 (2019): 337–41. http://dx.doi.org/10.5505/vtd.2019.98470.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Khoo, Weng Hua, Guy Ledergor, Assaf Weiner, Daniel L. Roden, Rachael L. Terry, Michelle M. McDonald, Ryan C. Chai, et al. "A niche-dependent myeloid transcriptome signature defines dormant myeloma cells." Blood 134, no. 1 (July 4, 2019): 30–43. http://dx.doi.org/10.1182/blood.2018880930.

Full text

Abstract:

Abstract The era of targeted therapies has seen significant improvements in depth of response, progression-free survival, and overall survival for patients with multiple myeloma. Despite these improvements in clinical outcome, patients inevitably relapse and require further treatment. Drug-resistant dormant myeloma cells that reside in specific niches within the skeleton are considered a basis of disease relapse but remain elusive and difficult to study. Here, we developed a method to sequence the transcriptome of individual dormant myeloma cells from the bones of tumor-bearing mice. Our analyses show that dormant myeloma cells express a distinct transcriptome signature enriched for immune genes and, unexpectedly, genes associated with myeloid cell differentiation. These genes were switched on by coculture with osteoblastic cells. Targeting AXL, a gene highly expressed by dormant cells, using small-molecule inhibitors released cells from dormancy and promoted their proliferation. Analysis of the expression of AXL and coregulated genes in human cohorts showed that healthy human controls and patients with monoclonal gammopathy of uncertain significance expressed higher levels of the dormancy signature genes than patients with multiple myeloma. Furthermore, in patients with multiple myeloma, the expression of this myeloid transcriptome signature translated into a twofold increase in overall survival, indicating that this dormancy signature may be a marker of disease progression. Thus, engagement of myeloma cells with the osteoblastic niche induces expression of a suite of myeloid genes that predicts disease progression and that comprises potential drug targets to eradicate dormant myeloma cells.

APA, Harvard, Vancouver, ISO, and other styles

5

Winterbottom, A. P., and A. S. Shaw. "Imaging patients with myeloma." Clinical Radiology 64, no. 1 (January 2009): 1–11. http://dx.doi.org/10.1016/j.crad.2008.07.006.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Bayer-Garner, Ilene B., Mary R. Schwartz, Pei Lin, and Bruce R. Smoller. "CD117, but Not Lysozyme, Is Positive in Cutaneous Plasmacytoma." Archives of Pathology & Laboratory Medicine 127, no. 12 (December 1, 2003): 1596–98. http://dx.doi.org/10.5858/2003-127-1596-cbnlip.

Full text

Abstract:

Abstract Context.—CD117 (c-Kit) and lysozyme are frequently expressed by myeloblasts and are sensitive markers for the diagnosis of extramedullary myeloid tumor. The diagnosis of cutaneous plasmacytoma presents a degree of difficulty, particularly with the plasmablastic variant, which can mimic hematologic as well as epithelioid malignancies. Approximately 25% of multiple myelomas express CD117 in the bone marrow by flow cytometry. Lysozyme immunoreactivity has been previously shown in 30% of poorly differentiated myelomas, while it is nonreactive in nonmalignant plasma cells. Objective.—To ascertain whether CD117 and lysozyme can aid in the diagnosis of cutaneous plasmacytomas, particularly the plasmablastic type. Design.—Pathology reports of 2357 patients with a diagnosis of multiple myeloma were reviewed to find 13 cutaneous plasmacytomas (8 Bartl grade II, 5 Bartl grade III). Formalin-fixed, paraffin-embedded tissue sections were stained with CD117 and lysozyme on the Dako Autostainer system. Setting.—Patients with the diagnosis of multiple myeloma who developed cutaneous plasmacytoma(s). Results.—The cutaneous plasmacytomas uniformly expressed CD117 in a cytoplasmic or membranous and cytoplasmic distribution with varying degrees of staining intensity unrelated to the Bartl grade of the lesion, while they were uniformly negative for lysozyme. Conclusions.—CD117 is a sensitive marker for malignant plasma cells in paraffin-embedded tissue, while lysozyme does not help identify poorly differentiated malignant plasma cells. While CD117 alone does not distinguish extramedullary myeloid tumor from poorly differentiated myeloma, the combination of CD117 and lysozyme may allow their differentiation. The possibility of c-kit inhibitors being used in the treatment of other hematopoietic malignancies allows speculation regarding implications for the treatment of multiple myeloma.

APA, Harvard, Vancouver, ISO, and other styles

7

Войцеховский, Валерий, Valeriy Voytsekhovskiy, Татьяна Заболотских, Tat'yana Zabolotskikh, Алексей Григоренко, Aleksey Grigorenko, Екатерина Филатова, and Ekaterina Filatova. "DAMAGE OF THE BRONCHOPULMONARY SYSTEM IN PATIENTS WITH CHRONIC HEMOBLASTOSIS." Bulletin physiology and pathology of respiration 1, no. 69 (October 5, 2018): 25–35. http://dx.doi.org/10.12737/article_5b975083a62278.59044240.

Full text

Abstract:

In 185 patients with chronic hemoblastosis (chronic lymphocytic leukemia, chronic myeloid leukemia, idiopathic myelofibrosis, multiple myeloma) after autopsy, the pathology of the bronchopulmonary system was studied. It was found out that in addition to immunodeficiency, an important role in the occurrence of respiratory diseases in chronic lymphocytic leukemia, as well as in chronic myeloid leukemia and idiopathic myelofibrosis in the stage of blast crisis is played by specific leukemic infiltration of the lungs, bronchi, pleura and diaphragm; the presence of leukostasis in the vessels of medium and small caliber with violation of microcirculation; compression of the diaphragm by significantly increased spleen and liver; in some cases (especially in chronic lymphocytic leukemia) hyperplasia of the lymphoid follicles of the bronchial tree. In chronic myeloid leukemia and idiopathic myelofibrosis, hyperthrombocytosis with the development of the sludge syndrome in small vessels of the lungs is essential. Pulmonary localization of inflammatory processes in patients with multiple myeloma is facilitated by lymphoid and plasma cell infiltration of the lungs, paraproteinosis of the lungs, localization of myeloma nodes in the ribs, lung tissue and bronchi.

APA, Harvard, Vancouver, ISO, and other styles

8

Kubiczkova-Besse, Lenka, Lenka Sedlarikova, Fedor Kryukov, Lenka Radova, Jana Nekvindova, Pavel Nemec, Daniela Drandi, et al. "Circulating Mir-130a in Multiple Myeloma and Extramedullary Myeloma Patients." Blood 124, no. 21 (December 6, 2014): 2043. http://dx.doi.org/10.1182/blood.v124.21.2043.2043.

Full text

Abstract:

Abstract Background MicroRNAs (miRNAs) are a class of short, non-coding, single stranded RNAs regulating a broad spectrum of processes. Circulating miRNAs are an important emerging biomarker in cancer as well as a possible non-invasive diagnostic solution for a wide range of clinical disorders due to their high stability and association with disease state, although their source still remains uncertain. In multiple myeloma (MM), a plasma cell malignancy, circulating miRNAs have been reported to have a diagnostic and prognostic potential. It is therefore plausible to assume that they are involved in pathogenesis of this disease and thus could be used as diagnostic tool not only for MM, its extramedullary (EM) form but also for monitoring the clinical course of the disease. Therefore, in this study, we aimed to identify such miRNAs. Methods Screening analysis of 667 miRNAs was performed on 5 EM serum samples, 5 newly diagnosed MM samples and 6 healthy donors (HD) serum samples using TaqMan Low Density Arrays (TLDA) from Life Technologies. QPCR was performed for miR-130a on 118 serum samples obtained in Brno from newly diagnosed MM patients (pts) (35 pts), primary and secondary EM (35 pts), relapsed MM (18 pts) and HD (30). Further, 45 serum samples (12 diagnostic and 33 follow-up) of pts reaching VGPR/better response, enrolled in Italian CRD/MEL-200 and EMN-02 studies were used for circulating miRNA estimation. Receiver Operating Characteristic (ROC) analysis was used to calculate specificity and sensitivity of the miRNA as a biomarker. Biochemical characteristics were also available for EM and MM pts from Brno. P values <0.05 were considered as significant. Results TLDA profiling revealed 14 deregulated miRNAs (all p<0.05, adjusted p<0.41) between MM pts and EM pts, and 20 miRNAs were on the top of the list of deregulated miRNAs between EM and HD serum samples (all p<0.05, adjusted p<0.40). MiR-130a was chosen for further verification by qPCR as it was on the top of the list of deregulated miRNAs between the groups. qPCR revealed that level of miR-130a was significantly decreased in MM and EM samples when compared with HD (all p<0.005); moreover, level of miR-130a was decreased also in EM when compared with MM sera (p<0.06). To discriminate EM pts from other groups, ROC curve was calculated. It revealed that miR-130a is potent to distinguish EM pts from HD with area under the curve (AUC) = 0.805, specificity of 86.7% and sensitivity of 65.7% using cut-off value = 3377 copies/1ng of miRNA/RNA. Most importantly, miR-130a was able to distinguish EM pts from newly diagnosed MM pts with AUC = 0.628, specificity of 94.3% and sensitivity of 28.6% using cut-off value = 1438 copies/1ng of miRNA/RNA, and EM pts from MM pts in relapse with AUC = 0.702, specificity of 94.4% and sensitivity of 28.6% using cut-off value = 1438 copies/1ng of miRNA/RNA. In the cohort of EM pts, miR-130a significantly correlated with most of clinically relevant parameters; there was a positive correlation with level of hemoglobin and thrombocytes count (rs=0.397 and 0.439, all p<0.05) and a negative correlation with levels of monoclonal immunoglobulin, β2-microglobulin and C-reactive protein (rs=-0.398, -0.427 and -0.488, all p<0.05) and it was also associated with higher ISS stage (p=0.017). Further, in the analysis of miR-130a dynamics in follow-up samples from Italy, we observed increase of miR-130a levels in 8/12 MM pts during the follow-up sampling (p<0.06) in comparison with diagnostic samples, whereas in remaining 4 MM pts it remained stable or decreased. Conclusions In this study, miR-130a was decreased in serum samples of pts developing EM disease and distinguished EM pts from newly diagnosed MM pts and relapsed/progressed MM pts with specificity over 90%. Further, we observed increased level of miR-130a in the follow-up samples of MM pts. It suggests that miR-130a could be associated with EM disease; however, underlying biology and origin of miR-130a still remains to be explored. Work was supported by grants IGA NT 12130, NT 14575 and NT 13190. Disclosures Palumbo: Amgen: Consultancy, Honoraria; Bristol-Myers Squibb: Consultancy, Honoraria; Array BioPharma: Honoraria; Genmab A/S: Consultancy, Honoraria; Celgene: Consultancy, Honoraria; Janssen-Cilag: Consultancy, Honoraria; Millennium Pharmaceuticals, Inc.: Consultancy, Honoraria; Onyx Pharmaceuticals: Consultancy, Honoraria; Sanofi Aventis: Honoraria.

APA, Harvard, Vancouver, ISO, and other styles

9

Kelly, Mary, and Maura Dowling. "Patients’ lived experience of myeloma." Nursing Standard 25, no. 28 (March 16, 2011): 38–44. http://dx.doi.org/10.7748/ns.25.28.38.s53.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Mateos, María-Victoria. "Management of asymptomatic myeloma patients." Expert Review of Hematology 8, no. 1 (November 3, 2014): 19–27. http://dx.doi.org/10.1586/17474086.2015.978852.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Kelly, Mary, and Maura Dowling. "Patients’ lived experience of myeloma." Nursing Standard 25, no. 28 (March 16, 2011): 38–44. http://dx.doi.org/10.7748/ns2011.03.25.28.38.c8397.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Gemmiti, Amanda L., and Teresa C. Gentile. "CMV Reactivation in Myeloma Patients." Clinical Infection and Immunity 3, no. 3-4 (2018): 87–88. http://dx.doi.org/10.14740/cii68w.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Zweegman, Sonja, Monika Engelhardt, and Alessandra Larocca. "Elderly patients with multiple myeloma." Current Opinion in Oncology 29, no. 5 (September 2017): 315–21. http://dx.doi.org/10.1097/cco.0000000000000395.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Mejbar, Rim, Zineb Benlachhab, Nadia Kabbali, and Tariq Sqalli. "SP043MULTIPLE MYELOMA IN YOUNG PATIENTS." Nephrology Dialysis Transplantation 33, suppl_1 (May 1, 2018): i360. http://dx.doi.org/10.1093/ndt/gfy104.sp043.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Bonn, Dorothy. "Better prospects for myeloma patients." Lancet Oncology 1, no. 1 (September 2000): 7. http://dx.doi.org/10.1016/s1470-2045(00)00093-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Kaplon, M. K. "Multiple myeloma in young patients." Archives of Internal Medicine 157, no. 3 (February 10, 1997): 361a—361. http://dx.doi.org/10.1001/archinte.157.3.361a.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Roman, Sara, Suzanne R. Fanning, Saeeda Chowdhury, Elizabeth Cull, Valorie Brooks, and Lynette Gibson. "Cognition in Multiple Myeloma Patients." Biology of Blood and Marrow Transplantation 25, no. 3 (March 2019): S374—S375. http://dx.doi.org/10.1016/j.bbmt.2018.12.608.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Kaplon, Michael K. "Multiple Myeloma in Young Patients." Archives of Internal Medicine 157, no. 3 (February 10, 1997): 361. http://dx.doi.org/10.1001/archinte.1997.00440240127022.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Karia, Sumit, and Meghna Ruparelia. "Multiple Myeloma." InnovAiT: Education and inspiration for general practice 4, no. 11 (June 28, 2011): 617–23. http://dx.doi.org/10.1093/innovait/inr030.

Full text

Abstract:

Multiple myeloma is a rare but serious haematological malignancy which at any one time affects between 20 000 and 30 000 patients in the UK. Prior to diagnosis, most of these patients present to primary care with non-specific symptoms. A delay in diagnosis is associated with an increase in complications, such as anaemia, bone disease and renal failure. This may have an impact on patients' quality of life as well as their ability to tolerate toxic treatment options. The key steps in primary care are to identify those patients with symptoms suggestive of multiple myeloma, carry out timely investigations and be aware of the appropriate referral pathways. Once the diagnosis is confirmed, the GP has a vital role in supporting the patient throughout what is, for most, a chronic debilitating illness.

APA, Harvard, Vancouver, ISO, and other styles

20

Song, Jinming, Hailing Zhang, Xiaohui Zhang, Mohammad Hussaini, Ning Dong, Lynn C. Moscinski, Kenneth H. Shain, Melissa Alsina, Taiga Nishihori, and Ling Zhang. "Molecular Insights into Clonal Hematopoiesis and Therapy-Related Myeloid Neoplasm in Patients with Multiple Myeloma and Cytopenia(s)." Blood 136, Supplement 1 (November 5, 2020): 6–7. http://dx.doi.org/10.1182/blood-2020-141656.

Full text

Abstract:

Background: Multiple myeloma (MM) is a clonal plasma cell neoplasm typically associated with chronic therapy and resultant potential toxicities, including clonal cytopenias, myelodysplastic syndrome (MDS), or therapy-related myeloid neoplasms (tMN). Early identification of myelodysplasia is important for patient management and outcome. Next generation sequencing (NGS) is playing an ever increasing role in this field. Materials and Methods: The retrospective study was approved by Moffitt institutional review board (IRB). We searched our in-house NGS database with ~6000 patients and clinical databases to identify the patients with MM and sustained cytopenia with accompanying NGS data. The NGS results were analyzed for associations with myeloma and myelodysplasia. Results: Of the 196 identified patients identified (Table 1), there were 114 males (58%) and 82 females (42%) with a median age of 68 years. Eighty-four myeloma patients with cytopenia (43%) were found to have one or more somatic mutations and 112 patients (57%) showed no mutations. The most frequently mutated genes are as following: TP53 (12%), DNMT3A (8%), TET2 (6%), ASXL1 (5%), KRAS (5%), ETV6 (3%), RUNX1 (2%), CUX1 (2%), BCOR (2%), SF3B1 (2%), ZRSR2 (2%), EZH2 (2%), IDH2 (2%), SRSF2 (2%), and BRAF (1%). We divided the patients into four groups according their disease status at the time of NGS testing: 1) patients with myeloma but no myelodysplasia (MM_Only, 105 patients and 53.57%); 2) Patients with myelodysplasia but no overt residual myeloma (Myelodysplasia_Only, 14 patients, 7.14%); 3) Patients with both myeloma and myelodysplasia (MM+Myelodysplasia, 27 patients, 13.78%); 4) Patients with neither myeloma or myelodysplasia (Negative_for_Both, 50 patients, 25.51%). The "Myelodysplasia" in this study is defined as having either overt morphologic dysplasia (>10% of the lineage cells), or equivocal dysplasia but having myeloid-related (non-myeloma) cytogenetic abnormalities. NGS results were not included in the classification to assess the added diagnostic value of NGS. The Mutational profiles of the four disease groups are displayed in Figure 1 and compared in Table 1 and 2. The MM+Myelodysplasia group showed highest percentage of mutations (88.89% of patients tested), followed by Myelodysplasia_Only group (57.14%) and MM_Only group (35.24%), with Negative_for_Both group showing the lowest mutation rate (30.00%). The average number of somatic mutations/case also followed the same order: 1.63, 1.00, 0.48, and 0.36, respectively. Of the 196 patients, 58 patients (29.59%) had no morphologic dysplasia or myeloid-related cytogenetic abnormalities but showed one or more somatic mutations by NGS. These patients harbored clonal cytopenia of uncertain significance (CCUS) clones and would have been missed without NGS testing. Of these 58 patients, retrospective review actually identified 7 patients with morphologic dysplasia and were reclassified as MDS. Further mutational analysis revealed the following interesting findings. ASXL1, DNMT3A, KRAS, and SF3B1 mutations showed highest frequencies in MM+Myelodysplaisa group when compared with other 3 groups (Table 2), indicating a close association with myelodysplasia development in patients with persistent myeloma. In contract, among the 4 groups, RUNX1 mutations were most common in Myelodysplasia_only patients, suggesting a potential alternative pathway for myelodysplasia development in patient with myeloma in remission. It is possible that presence of myeloma clones create different evolution pressure on neoplastic myeloid clones. TP53 mutations were present in MM_Only group, but were much more frequent in patients with MM+Myelodysplasia and Myelodysplasia_only groups. The presence of TP53 mutations might therefore suggest increased risk for myelodysplasia. Finally, TET2 were similar between these groups and therefore not of significant diagnostic value. Conclusion: NGS testing is valuable in identifying CCUS, MDS, or tMN in myeloma patients, especially in those with no morphologic or cytogenetic abnormalities. Statistically significant differences are seen in the mutational profiles of the four groups of patients, suggestive of different roles in myelodysplasia development. Further studies are necessary to better distinguish the origin of these mutations as being derived from the myeloma versus the myeloid components of the disease. Disclosures Hussaini: Stemline: Consultancy; Amgen: Consultancy; Janssen: Consultancy; Adaptive: Consultancy; Boston Biomedical: Consultancy. Shain:Karyopharm: Research Funding, Speakers Bureau; AbbVie: Research Funding; Takeda: Honoraria, Speakers Bureau; Sanofi/Genzyme: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Amgen: Speakers Bureau; GlaxoSmithKline: Speakers Bureau; Adaptive: Consultancy, Honoraria; BMS: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Janssen: Honoraria, Speakers Bureau; Celgene: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Nishihori:Novartis: Other: Research support to institution; Karyopharm: Other: Research support to institution.

APA, Harvard, Vancouver, ISO, and other styles

21

Bladé, Joan, Ma Teresa Cibeira, Laura Rosiñol, and Carlos Fernández de Larrea. "Extramedullary Myeloma." Blood 114, no. 22 (November 20, 2009): SCI—5—SCI—5. http://dx.doi.org/10.1182/blood.v114.22.sci-5.sci-5.

Full text

Abstract:

Abstract Abstract SCI-5 Multiple myeloma (MM) is characterized by a proliferation of plasma cells (PC) with strong dependence on the bone marrow (BM) microenvironment. In fact, stromal cells and adhesion molecules play a crucial role in the pathogenesis of MM as well as in the homing of myeloma cells within the bone marrow, in both human myeloma and in murine plasmacytoma models. Virtually, all patients with MM will develop skeletal involvement as result of an imbalanced bone remodelling. This imbalance results in severe osteopenia and/or generalized bone lytic lesions. However, some patients develop large lytic bone lesions, as result of bone replacement by PCs, which can be considered as extramedullary tumors. Importantly, about 15% of patients with MM have soft-tissue extramedullary plasmacytomas (EMP) at diagnosis and an additional 20% develop EMP during the course of the disease. It has been suggested that patients relapsing after Allo-RIC transplantation have even a higher rate of EMP. Although the ultimate mechanisms resulting in extramedullary spread in MM remain unclear, it is likely that in patients with aggressive myeloma or at disease relapse, myeloma cells become stromal independent this favouring their proliferation and survival in the absence of the BM microenvironment. The development of extramedullary disease in MM can show different patterns. First, local soft-tissue growth from adjacent bone lesions. Second, hematogenous spread with: 1) single or multiple large subcutaneous plasmacytomas, 2) metastatic like nodules in the skin or in organs or tissues such as liver, kidney, breast or lymph nodes, and 3) CNS involvement (meningeal myelomatosis). Finally, extramedullary myeloma growth can be triggered by surgical procedures leading to the appearance of plasmacytomas at the sites of catheter insertion, laparotomy or sternotomy scars, and even local dissemination through bone surgery. In our experience, the frequency of high-risk cytogenetics –t/4;14), t(14;16) and 17pdel- by BMPC FISH analysis at diagnosis is similar in patients with or without EMP (22% vs.18%). Despite this fact, patients with extramedullary involvement usually have a more aggressive disease. In many instances, the plasma cells from EMP, particularly at relapse, show an immature or plasmablastic morphology, and highly aberrant phenotypic cell lines have been generated from extramedullary human tumors. Whether or not plasma cells from extramedullary sites have a different phenotype or cytogenetic features than the BMPC has not been reported. Soft-tissue plasmacytomas do not respond to thalidomide and cases of extramedullary progression in patients in serological response have been observed. In contrast, dramatic responses of EMP to bortezomib have been reported. In our experience, patients with extramedullary plasmacytomas show a significantly higher progressive disease rate to the induction pre-transplant regimens compared with those with no extramedullary disease (34% vs. 11%). In summary, up to one third of patients with MM will develop EMP, this being associated with a poor response to therapy and outcome. A better understanding of the mechanisms of myeloma spread and on the biology of extramedullary tumors will hopefully result in better treatment possibilities. In this regard, there is evidence suggesting that plamacytomas in mice and humans exhibit some similarities and the selection of plasmacytomas related to MM subtypes might provide an excellent opportunity for preclinical drug testing. Disclosures Bladé: Celgene: Honoraria, Research Funding; Jansen-Cilag: Honoraria, Research Funding. Cibeira:Jansen-Cilag: Honoraria; Celgene: Honoraria. Rosiñol:Jansen-Cilag: Honoraria; Celgene: Honoraria.

APA, Harvard, Vancouver, ISO, and other styles

22

Dass, Jasmita, Sudheer Arava, Pravas Chandra Mishra, Amit Kumar Dinda, and Hara Prasad Pati. "Role of CD138, CD56, and light chain immunohistochemistry in suspected and diagnosed plasma cell myeloma: A prospective study." South Asian Journal of Cancer 08, no. 01 (January 2019): 60–64. http://dx.doi.org/10.4103/sajc.sajc_64_17.

Full text

Abstract:

Abstract Introduction: Plasma cells (PCs) have conventionally been counted on the bone marrow aspirate, and small focal involvement may be missed even on bone marrow biopsy sections. Material and Methods: We aimed to study the role of CD138, CD56, anti-κ, and anti-λ immunohistochemistry (IHC) to separate PC myeloma from reactive plasmacytosis and to study the utility of these in cases suspected as myelomas and lacking >10% PCs on bone marrow aspirate. The study comprised 35 diagnosed myelomas, 20 reactive plasmacytosis, and 19 M-band positive suspected myelomas. CD138 IHC was performed on all cases along with CD56, anti-κ, and anti-λ IHC. PCs were counted on CD138-immunostained sections by manual count and by image analysis. In addition, CD56 expression was correlated with clinical features in diagnosed myeloma group. Results: In all cases, both manual counts and image analysis, PC counts were significantly higher on the CD138 stained sections than bone marrow aspirates. It was seen that the manual PC counts and image analysis counts were equivalent in diagnosed myeloma cases. CD56 expression was seen in ~62.85% diagnosed myeloma cases while it was negative in cases of reactive plasmacytosis. CD56 expression was significantly higher in patients with lytic lesions (78.26% vs. 21.74%). CD138, anti-κ, and anti-λ IHC also helped classify 11/19 (57.8%) cases correctly. Conclusion: The use of CD138 along with the light chain and CD56 IHC adds a high diagnostic value in myeloma patients and suspected myeloma cases. The PCs can be counted manually on the CD138-immunostained sections and correlate well with the counts obtained by image analysis.

APA, Harvard, Vancouver, ISO, and other styles

23

Binder, Moritz, S. Vincent Rajkumar, Arjun Lakshman, Martha Q. Lacy, Morie A. Gertz, Francis K. Buadi, Angela Dispenzieri, et al. "Expected Survival in Patients with Smoldering Multiple Myeloma and Multiple Myeloma." Blood 132, Supplement 1 (November 29, 2018): 4497. http://dx.doi.org/10.1182/blood-2018-99-118084.

Full text

Abstract:

Abstract Background: The introduction of novel therapeutics has led to improved outcomes in patients with multiple myeloma (MM). MM and its precursor lesion smoldering multiple myeloma (SMM) have traditionally been associated with increased mortality despite treatment. We aimed to assess the impact of a diagnosis of SMM and MM compared to the general population in the context of established prognostic factors. Methods: We studied the overall survival of 1697 patients with smoldering multiple myeloma (SMM, n = 582) and multiple myeloma (MM, n = 1115) diagnosed at Mayo Clinic between 01/2005 and 12/2015. Expected survival accounting for age and sex was calculated using the United States general population (US) as the reference group. Observed and expected overall survival was expressed as the standardized mortality ratio (SMR) of observed to expected deaths. Kaplan-Meier overall survival estimates were calculated and the log-rank test was used to compare overall survival in subgroups. The subgroups of interest were based on the International Staging System (ISS) and the presence of fluorescence in situ hybridization (FISH) high-risk cytogenetics: t(4;14), t(14;16), t(14;20), and del(17p). Proportional hazards regression models were used to assess the associations between the aforementioned prognostic factors and overall survival. P-values below 0.05 were considered statistically significant. Results: The median age at diagnosis in patients with SMM and MM was 65 (32 - 92) and 63 years (24 - 90), respectively. Two hundred forty-nine patients (57%) and 663 (60%) were male. The median follow-up in patients with SMM and MM was 4.7 (0.1 - 11.0) and 2.6 years (0.2 - 9.5). The median overall survival for patients with SMM and MM was 9.0 (95% CI 8.4 - 9.7) and 7.9 years (6.4 - 8.7). With age- and sex-matched population controls as the reference, the SMRs in patients with SMM and MM were 2.6 (95% CI 2.2 - 3.0) and 4.6 (4.1 - 5.2). Among those MM patients with available data on ISS staging and FISH cytogenetics, 30% (236/780) had ISS III and 21% (188/878) had high-risk cytogenetics. Patients with MM (compared to SMM) experienced worse overall survival (HR 1.5, 95% CI 1.2 - 1.8, p < 0.001, n = 1697). Patients with ISS I/II MM (compared to SMM) experienced similar survival (HR 1.0, 95% CI 0.8 - 1.3, p = 0.698, n = 1131). Patients with ISS III MM (compared to MM with high-risk cytogenetics) experienced similar survival (HR 1.3, 95% CI 0.9 - 2.0, p = 0.128, n = 329). Conclusions: Patients with SMM and MM in this cohort experienced excess mortality compared to the general population. In the absence of universal screening the true morbidity and mortality of patients with SMM and MM remains unknown and is likely overestimated in hospital-based cohorts. Overall survival in patients diagnosed with SMM and patients with ISS I/II MM receiving contemporary anti-myeloma therapy was clinically indistinguishable. Patients treated for ISS III MM experienced overall survival similar to patients with cytogenetic high-risk disease. MM remains associated with excess mortality, the magnitude of which varies considerably based on the presence of additional tumor and host factors. The outcomes with modern therapy among the ISS I/II patients highlight the potential for improving outcomes of SMM by early intervention, especially for the higher risk patients. Figure. Figure. Disclosures Lacy: Celgene: Research Funding. Gertz:Medscape: Consultancy; Alnylam: Honoraria; janssen: Consultancy; spectrum: Consultancy, Honoraria; Ionis: Honoraria; annexon: Consultancy; celgene: Consultancy; Teva: Consultancy; Prothena: Honoraria; Apellis: Consultancy; Abbvie: Consultancy; Physicians Education Resource: Consultancy; Amgen: Consultancy; Research to Practice: Consultancy. Dispenzieri:Celgene, Takeda, Prothena, Jannsen, Pfizer, Alnylam, GSK: Research Funding. Russell:Vyriad: Equity Ownership. Kapoor:Takeda: Research Funding; Celgene: Research Funding. Kumar:Roche: Research Funding; AbbVie: Membership on an entity's Board of Directors or advisory committees, Research Funding; Celgene: Membership on an entity's Board of Directors or advisory committees, Research Funding; AbbVie: Membership on an entity's Board of Directors or advisory committees, Research Funding; KITE: Membership on an entity's Board of Directors or advisory committees, Research Funding; KITE: Membership on an entity's Board of Directors or advisory committees, Research Funding; Janssen: Membership on an entity's Board of Directors or advisory committees, Research Funding; Janssen: Membership on an entity's Board of Directors or advisory committees, Research Funding; Oncopeptides: Membership on an entity's Board of Directors or advisory committees; Novartis: Research Funding; Celgene: Membership on an entity's Board of Directors or advisory committees, Research Funding; Takeda: Membership on an entity's Board of Directors or advisory committees; Merck: Membership on an entity's Board of Directors or advisory committees, Research Funding.

APA, Harvard, Vancouver, ISO, and other styles

24

Abdalla, A. O., P. Kokhaei, L. Hansson, H. Mellstedt, and A. Österborg. "Idiotype vaccination in patients with myeloma reduced circulating myeloma cells (CMC)." Annals of Oncology 19, no. 6 (June 2008): 1172–79. http://dx.doi.org/10.1093/annonc/mdn017.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Yokoyama, Kenji. "Thrombosis in Lymphoma Patients and in Myeloma Patients." Keio Journal of Medicine 64, no. 3 (2015): 37–43. http://dx.doi.org/10.2302/kjm.2014-0017-re.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Fan, Jianling, Jian Hou, Juan Du, Lina Jin, Lihui Peng, Baoan Chen, Hao Xi, et al. "Macrofocal Multple Myeloma Is a Particular Subgroup of Multiple Myeloma." Blood 126, no. 23 (December 3, 2015): 1855. http://dx.doi.org/10.1182/blood.v126.23.1855.1855.

Full text

Abstract:

Abstract Some young multiple myeloma (MM) patients, coined macrofocal MM, have been reported to present with multiple lytic bone lesions and less than 10% bone marrow plasma cells (BMPCs). They usually have low tumor burden and favorable outcome. To further understand the clinical and laboratory features of macrofocal MM, we retrospectively analyzed about 1000 symptomatic MM patients of two centers and found that 49 (4.9%) patients fulfilled the criteria of macrofocal MM. Median age was 54 years; 39 (80%) were male. The immunoglobulin subtype included IgG (13), IgA (5), IgD (4), light chain only (4) and non-secretory type (23). International Staging System (ISS) stage 1 in 45 (92%), and no stage 3 patient. Durie-Salmon (DS) Staging System stage 3A in 48 (98%), and 2A in 1. Extramedullary plasmacytomas (EMPs) in 39 (80%) patients. The mean percentage of BMPCs was 2.1%, and 44 (90%) patients had less than 5% BMPCs. No patients had hypercalcemia and renal impairment. FISH cytogenetics, available in 11 patients, showed IgH translocation in 7, 13q del in 2, t(4;14) in 1, 1q21 amp in 6 and p53 del in 2 patients. Serum free light chain (sFLC), available in 14 patients, showed abnormal sFLC in 7 of 14 patients and 4 in 7 non-secretory type patients. Thirty eight (77.6%) patients received new drug-based induction therapies and 14 patients received autologous stem cell transplantation (ASCT) as consolidation therapy. After a median follow-up of 36 months,the estimated median progression-free survival (PFS) was 41 months and the median overall survival time (OS) had not been reached. Forty four macrofocal MM with ISS stage 1 and DS stage 3A were compared to all (93) typical symptomatic MM patients who were diagnosed at the same period with the same stages according to both ISS and DS Staging System. For macrofocal MM, there were significantly more male patients and EMPs, higher hemoglobin levels and lowerb2-microglobulin (b2M) levels than that of typical MM. There were no significant differences in the proportions of patients received novel agents-based chemotherapy and ASCT between two groups, however, the estimated median PFS of macrofocal MM was significant superior to typical MM (41 vs 23 months, respectively; P= 0.001) (Figure 1), and the estimated median OS was also better in macrofocal MM than typical MM (not reached vs 61 months; P= 0.004) (Figure 2). Multivariate analysis showed that only the type of disease was the independent prognostic factor of both PFS and OS. In summary, Macrofocal MM is a particular subgroup of MM with multiple bone lesions and lower tumor burden, higher frequency of EMPs, and better survival than typical symptomatic MM. Figure 1. Figure 1. Figure 2. Figure 2. Disclosures Fan: The National Natural Science Foundation of China: Research Funding. Hou:Novartis: Membership on an entity's Board of Directors or advisory committees.

APA, Harvard, Vancouver, ISO, and other styles

27

Osterborg, A., M. Bjorkholm, M. Bjoreman, G. Brenning, K. Carlson, F. Celsing, G. Gahrton, G. Grimfors, H. Gyllenhammar, and R. Hast. "Natural interferon-alpha in combination with melphalan/prednisone versus melphalan/prednisone in the treatment of multiple myeloma stages II and III: a randomized study from the Myeloma Group of Central Sweden." Blood 81, no. 6 (March 15, 1993): 1428–34. http://dx.doi.org/10.1182/blood.v81.6.1428.1428.

Full text

Abstract:

Abstract Three hundred thirty-five previously untreated patients with multiple myeloma in clinical stages II and III entered a randomized trial comparing intermittent oral melphalan and prednisone (MP) therapy (n = 171) with MP in combination with natural (leukocyte-derived) alpha- interferon (MP/IFN) (n = 164). The treatment groups were comparable with regard to major prognostic factors. The response frequency was 42% in the MP group and 68% in the MP/IFN group (P < .0001). Eighty-five percent of IgA myelomas and 71% of Bence-Jones myelomas responded to MP/IFN compared with 48% and 27%, respectively, to MP treatment (P = .001). There was no difference in the overall survival between the two treatment groups. However, the survival of 72 patients with IgA or Bence-Jones myeloma randomized to receive MP/IFN was significantly longer (median 32 months) than that of 71 patients treated with MP (median 17 months) (p < .05). No statistically significant difference in response frequency (60% v 46%) or survival was found for patients with IgG myeloma. Hematologic toxicity, WHO grades III and IV, was higher in the MP/IFN group (48%) than in the MP group (33%) (P <.05) during the induction treatment period. Flulike syndrome was observed in 68% of patients receiving MP/IFN. The results show that MP/IFN is a well-tolerated treatment regimen, superior to MP for remission induction, and it improves significantly the overall survival for patients with IgA and Bence-Jones myelomas.

APA, Harvard, Vancouver, ISO, and other styles

28

Osterborg, A., M. Bjorkholm, M. Bjoreman, G. Brenning, K. Carlson, F. Celsing, G. Gahrton, G. Grimfors, H. Gyllenhammar, and R. Hast. "Natural interferon-alpha in combination with melphalan/prednisone versus melphalan/prednisone in the treatment of multiple myeloma stages II and III: a randomized study from the Myeloma Group of Central Sweden." Blood 81, no. 6 (March 15, 1993): 1428–34. http://dx.doi.org/10.1182/blood.v81.6.1428.bloodjournal8161428.

Full text

Abstract:

Three hundred thirty-five previously untreated patients with multiple myeloma in clinical stages II and III entered a randomized trial comparing intermittent oral melphalan and prednisone (MP) therapy (n = 171) with MP in combination with natural (leukocyte-derived) alpha- interferon (MP/IFN) (n = 164). The treatment groups were comparable with regard to major prognostic factors. The response frequency was 42% in the MP group and 68% in the MP/IFN group (P < .0001). Eighty-five percent of IgA myelomas and 71% of Bence-Jones myelomas responded to MP/IFN compared with 48% and 27%, respectively, to MP treatment (P = .001). There was no difference in the overall survival between the two treatment groups. However, the survival of 72 patients with IgA or Bence-Jones myeloma randomized to receive MP/IFN was significantly longer (median 32 months) than that of 71 patients treated with MP (median 17 months) (p < .05). No statistically significant difference in response frequency (60% v 46%) or survival was found for patients with IgG myeloma. Hematologic toxicity, WHO grades III and IV, was higher in the MP/IFN group (48%) than in the MP group (33%) (P <.05) during the induction treatment period. Flulike syndrome was observed in 68% of patients receiving MP/IFN. The results show that MP/IFN is a well-tolerated treatment regimen, superior to MP for remission induction, and it improves significantly the overall survival for patients with IgA and Bence-Jones myelomas.

APA, Harvard, Vancouver, ISO, and other styles

29

Kawano, M., I. Yamamoto, K. Iwato, H. Tanaka, H. Asaoku, O. Tanabe, H. Ishikawa, M. Nobuyoshi, Y. Ohmoto, and Y. Hirai. "Interleukin-1 beta rather than lymphotoxin as the major bone resorbing activity in human multiple myeloma." Blood 73, no. 6 (May 1, 1989): 1646–49. http://dx.doi.org/10.1182/blood.v73.6.1646.1646.

Full text

Abstract:

Abstract Human myeloma cells were purified from bone marrow aspirates from four patients having advanced myeloma, including one with common acute lymphoblastic leukemia antigen-positive myeloma. All of these myelomas had marked bone lytic lesions. From the culture supernatants of these purified myeloma cells, bone-resorbing activities were significantly revealed by 45Ca-release bone resorption assay, and IL-1 activities were also detected by IL-1 bioassay (mouse thymocyte comitogenic assay). Sandwich enzyme immunoassay for IL-1 alpha or IL-1 beta revealed that IL-1 beta was responsible for IL-1 activity of these culture supernatants. Furthermore, the bone resorbing activities of these culture supernatants were completely neutralized by pretreatment of anti-IL-1 beta, but not anti-IL-1 alpha antibody. By Northern blot analysis, IL-1 beta mRNA was identified from these myeloma cells. Therefore, it is concluded that myeloma cells produce IL-1 beta, which acts as bone-resorbing activity in multiple myeloma.

APA, Harvard, Vancouver, ISO, and other styles

30

Kawano, M., I. Yamamoto, K. Iwato, H. Tanaka, H. Asaoku, O. Tanabe, H. Ishikawa, M. Nobuyoshi, Y. Ohmoto, and Y. Hirai. "Interleukin-1 beta rather than lymphotoxin as the major bone resorbing activity in human multiple myeloma." Blood 73, no. 6 (May 1, 1989): 1646–49. http://dx.doi.org/10.1182/blood.v73.6.1646.bloodjournal7361646.

Full text

Abstract:

Human myeloma cells were purified from bone marrow aspirates from four patients having advanced myeloma, including one with common acute lymphoblastic leukemia antigen-positive myeloma. All of these myelomas had marked bone lytic lesions. From the culture supernatants of these purified myeloma cells, bone-resorbing activities were significantly revealed by 45Ca-release bone resorption assay, and IL-1 activities were also detected by IL-1 bioassay (mouse thymocyte comitogenic assay). Sandwich enzyme immunoassay for IL-1 alpha or IL-1 beta revealed that IL-1 beta was responsible for IL-1 activity of these culture supernatants. Furthermore, the bone resorbing activities of these culture supernatants were completely neutralized by pretreatment of anti-IL-1 beta, but not anti-IL-1 alpha antibody. By Northern blot analysis, IL-1 beta mRNA was identified from these myeloma cells. Therefore, it is concluded that myeloma cells produce IL-1 beta, which acts as bone-resorbing activity in multiple myeloma.

APA, Harvard, Vancouver, ISO, and other styles

31

Landgren, Ola, Susan Devesa, Pamela Mink, William F. Anderson, Brendan Weiss, Sigurdur Y. Kristinsson, and Katherine McGlynn. "African-American Multiple Myeloma Patients Have a Better Survival Than Caucasian Patients: a Population-Based Study Including 28,636 Patients." Blood 114, no. 22 (November 20, 2009): 1832. http://dx.doi.org/10.1182/blood.v114.22.1832.1832.

Full text

Abstract:

Abstract Abstract 1832 Poster Board I-858 Background Multiple myeloma is the most common hematologic malignancy in African-Americans with twice the incidence of Caucasians. Prior single center studies have reported poorer survival among African-American multiple myeloma patients. In contrast, recent data based on multiple myeloma patients who received autologous transplantation in an equal access health care system, showed comparable survival between African-Americans and Caucasians, suggesting that the reportedly poorer outcome for African-Americans may be due to inequalities in access to care. Also, based on publicly available cancer registry data, several publications have reported excess mortality rates for African-American multiple myeloma patients. We conducted a large population-based study including almost 30,000 multiple myeloma patients to evaluate survival patterns by race. Methods. Patient information was obtained from the Surveillance, Epidemiology and End Results (SEER) cancer registries of the National Cancer Institute. Data were drawn from the original nine SEER registries (Atlanta, Connecticut, Detroit, Hawaii, Iowa, New Mexico, San Francisco-Oakland, Seattle-Puget Sound, and Utah), which collectively cover approximately 10% of the U.S. population. Using the SEER*Stat statistical software package, we calculated 1-, 5-, and 10-year relative survival rates (RSR) of multiple myeloma patients diagnosed 1973-2004. We applied four calendar periods (1973-1979, 1980-1986, 1987-1993, and 1994-2004), follow-up through 2005 was included, and age at diagnosis was grouped into three strata (<50, 50-64, and 65+ years). Results We identified a total of 28,636 multiple myeloma patients (4,855 African-American; 23,781 Caucasian); 64% were 65 years or greater at diagnosis. When we included all patients, a comparison of survival rates in African-American and Caucasian males showed that African-American males had significantly better 5-year (32.2% vs. 28.7%) and 10-year (16.4% vs. 11.5%) RSRs (p<0.05). Similarly, African-American females had significantly better 1-year (73.3% vs. 70.2%) and 5-year (31.1% vs. 27.7%) RSRs than Caucasian females (p<0.05). When we examined survival patterns by calendar period (between 1973-1979 and 1994-2004), we found Caucasian patients to have significant improvements in the 1-year (from 67.1 to 72.4%), 5-year (from 24.1% to 31.7%), and 10-year RSR (from 9.9% to 14.9%). African-Americans also showed significantly improved 1-year RSRs (from 68.5% in 1973-1979 to 74.9% in 1994-2004) but the improvements in 5- and 10-year RSRs were not significant. When we examined survival patterns by age group, in the youngest age group (<50 years), both African-Americans and Caucasians improved 5- and 10-year RSRs, while 1-year RSR was improved for Caucasians only (from 80.9% to 84.9%). For patients 50-64 years, Caucasians had significantly improved 1-, 5-, and 10-year RSR; for African-Americans only 1-year RSR improvement was significant. Among patients 65+, there was no significant improved survival for African-Americans while Caucasians had improved 1-year (from 61.4% to 66.9%) and 5-year (from 19.6% to 24.7%) RSRs. Conclusions This large study of almost 30,000 patients found African-American multiple myeloma patients to have a significantly better prognosis than Caucasian patients, suggesting there is disease heterogeneity by race. After the introduction of newer therapies (autologous transplant, IMiDs, and bortezomib), Caucasian multiple myeloma patients showed a more pronounced survival benefit which might reflect inequalities in access to modern care; however, still African-Americans showed similar/better survival compared to Caucasians. Clinicians should be aware that the excess mortality rates for multiple myeloma among African-Americans, to a major degree, is a reflection of the fact that multiple myeloma is 2- to 3-fold more common among African-Americans. Future studies are needed to improve our understanding of the molecular basis for racial disparity patterns in multiple myeloma. Ultimately, such efforts will facilitate an improved understanding regarding disease subtype-specific benefits for individual agents, as well as mechanistic insights into drug sensitivity and resistance. Disclosures Weiss: The Binding Site, Inc.: Research Funding.

APA, Harvard, Vancouver, ISO, and other styles

32

Gras, J. "Pomalidomide for patients with multiple myeloma." Drugs of Today 49, no. 9 (2013): 555. http://dx.doi.org/10.1358/dot.2013.49.09.2017031.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Jones, Adam, Stella Bowcock, and Bernard Rachet. "Survival trends in elderly myeloma patients." European Journal of Haematology 106, no. 1 (October 29, 2020): 126–31. http://dx.doi.org/10.1111/ejh.13530.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Wang, Tzu‐Fei, and Aurélien Delluc. "Thromboprophylaxis in patients with multiple myeloma." British Journal of Haematology 190, no. 4 (May 12, 2020): 493–94. http://dx.doi.org/10.1111/bjh.16731.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

McClure, D., L. C. Lai, and C. Cornell. "Pseudohyperphosphataemia in patients with multiple myeloma." Journal of Clinical Pathology 45, no. 8 (August 1, 1992): 731–32. http://dx.doi.org/10.1136/jcp.45.8.731.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Larocca, Alessandra, and Antonio Palumbo. "How I treat fragile myeloma patients." Blood 126, no. 19 (November 5, 2015): 2179–85. http://dx.doi.org/10.1182/blood-2015-05-612960.

Full text

Abstract:

Abstract Multiple myeloma is a disease typical of elderly people, with a median age at diagnosis of 70 years. Much progress has been made in the past few years thanks to the introduction of new drugs. However, increases in survival were much less pronounced in patients aged 60 to 69 years, and no improvement was seen in older patients. Furthermore, the currently approved treatment regimens were tested in clinical trials with stringent inclusion criteria. Aging is associated with a high prevalence of frailty, that is, a state of increased vulnerability to stressors due to a critical decline in physiologic reserves. Elderly people may be categorized as fit or frail according to clinical, functional, cognitive, and socioeconomic criteria. The presence of frailty may complicate the management and outcome of myeloma patients. To date, the choice of treatment of myeloma patients has focused primarily on chronological age and performance status as markers of frailty. However, the elderly population is highly heterogeneous, and improved assessment strategies are needed to define the frailty profile of patients and provide them with the most adequate treatment, thus avoiding the overtreatment of frail patients and the undertreatment of fit patients. The geriatric assessment is a fundamental tool for the evaluation of cognitive and functional status.

APA, Harvard, Vancouver, ISO, and other styles

37

Varterasian, M., N. Janakiraman, C. Karanes, E. Abella, J. Uberti, J. Dragovic, S. B. K. Raman, et al. "Transplantation in Patients With Multiple Myeloma." American Journal of Clinical Oncology 20, no. 5 (October 1997): 462–66. http://dx.doi.org/10.1097/00000421-199710000-00005.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Nucci, Marcio, and Elias Anaissie. "Infections in Patients With Multiple Myeloma." Seminars in Hematology 46, no. 3 (July 2009): 277–88. http://dx.doi.org/10.1053/j.seminhematol.2009.03.006.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

WESTIN, E. "Lymphoma and myeloma in older patients." Seminars in Oncology 31, no. 2 (April 2004): 198–205. http://dx.doi.org/10.1053/j.seminoncol.2003.12.030.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Hopkins Tanne, J. "Drug helps patients with relapsed myeloma." BMJ 327, no. 7405 (July 3, 2003): 7—a—7. http://dx.doi.org/10.1136/bmj.327.7405.7-a.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

FESTEN, J. J. M., J. MARRINK, E. H. WAARD-KUIPER, and E. MANDEMA. "Immunoglobulins in Families of Myeloma Patients." Scandinavian Journal of Immunology 6, no. 9 (June 28, 2008): 887–96. http://dx.doi.org/10.1111/j.1365-3083.1977.tb00409.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Teh, Benjamin W., Simon J. Harrison, Leon J. Worth, Karin A. Thursky, and Monica A. Slavin. "Levofloxacin prophylaxis in patients with myeloma." Lancet Oncology 21, no. 2 (February 2020): e67. http://dx.doi.org/10.1016/s1470-2045(19)30824-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Albrich, Werner C., and Katia Boggian. "Levofloxacin prophylaxis in patients with myeloma." Lancet Oncology 21, no. 2 (February 2020): e68. http://dx.doi.org/10.1016/s1470-2045(20)30008-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Dufour, Inès, Juliette Raedemaeker, Fabio Andreozzi, Géraldine Verstraete, Sarah Bailly, Michel Delforge, Pauline Storms, et al. "COVID-19, impact on myeloma patients." Annals of Hematology 99, no. 8 (June 23, 2020): 1947–49. http://dx.doi.org/10.1007/s00277-020-04147-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Diamond, Evan, Oscar B. Lahoud, and Heather Landau. "Managing multiple myeloma in elderly patients." Leukemia & Lymphoma 59, no. 6 (August 28, 2017): 1300–1311. http://dx.doi.org/10.1080/10428194.2017.1365859.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Corthals, S. L., S. M. Sun, R. Kuiper, Y. de Knegt, A. Broyl, B. van der Holt, H. B. Beverloo, et al. "MicroRNA signatures characterize multiple myeloma patients." Leukemia 25, no. 11 (June 24, 2011): 1784–89. http://dx.doi.org/10.1038/leu.2011.147.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Crowley, Maeve P., Joseph A. Eustace, Susan I. O’Shea, and Oonagh M. Gilligan. "Venous Thromboembolism in Patients With Myeloma." Clinical and Applied Thrombosis/Hemostasis 20, no. 6 (January 30, 2014): 600–606. http://dx.doi.org/10.1177/1076029614521280.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Gonçalves, M., J. Teixeira Silva, A. Cabral, and Z. Santos. "Caregiving Experience of Multiple Myeloma Patients." European Psychiatry 33, S1 (March 2016): S498. http://dx.doi.org/10.1016/j.eurpsy.2016.01.1832.

Full text

Abstract:

IntroductionMultiple Myeloma (MM) is a cancer formed by malignant plasma cells. On a worldwide scale, it is estimated that about 86,000 incident cases occur annually. The aim of this report is to investigate the experience among multiple myeloma caregivers, assessing the mental adjustment to cancer diagnosis and the most prevalent psychopathology in the caregivers. This paper also attempts to establish the influence of the symptoms has in the caregiving experience.MethodsAll eligible caregivers will be approached during a regularly scheduled patient clinic visit and informed consent will be obtained prior to study participation. Data will be collected using the Mental Adjustment Scale to the Cancer Scale Partner (EAMC-F), Memorial Symptom Assessment Scale – Short Form, and Depression, Anxiety and Stress Scale (DASS-21).ResultsAccording to the literature caring for patients with MM can be different comparing with another form of cancer. It is an incurable form of cancer, although treatments improve life expectancy and quality of life. The authors are expecting to find high rates of depression, anxiety, unmet needs, and burden of care. The symptoms of the patients will probably influence the caregiving experience.ConclusionMM accounts for about 14% of all newly diagnosed hematological cancer, and it is estimated that its incidence will rise. The importance of psychiatric intervention in the multidimensional approach is becoming a recognized reality. This is essential in the treatment of psychiatric disorders, to improve prognosis and quality of life but also to reduce side effects of treatments and symptoms related to cancer.Disclosure of interestThe authors have not supplied their declaration of competing interest.

APA, Harvard, Vancouver, ISO, and other styles

49

Kyle, Robert A. "Multiple Myeloma in Young Patients-Reply." Archives of Internal Medicine 157, no. 3 (February 10, 1997): 361. http://dx.doi.org/10.1001/archinte.1997.00440240127023.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Chen, Y. H. "Hypoalbuminemia in patients with multiple myeloma." Archives of Internal Medicine 150, no. 3 (March 1, 1990): 605–10. http://dx.doi.org/10.1001/archinte.150.3.605.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!